Skip to content


  • Meeting abstract
  • Open Access

Tiotropium respimat® add-on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of TH2 inflammatory status

  • 1,
  • 2,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7,
  • 8,
  • 8,
  • 9 and
  • 10
Allergy, Asthma & Clinical Immunology201410 (Suppl 2) :A52

  • Published:


  • Budesonide
  • Salmeterol
  • Eosinophil Count
  • Tiotropium
  • Omalizumab


In patients with symptomatic asthma receiving ICS or ICS+LABA, Phase III studies have demonstrated improved lung function with tiotropium Respimat®, a once-daily long-acting anticholinergic bronchodilator. The efficacy of some treatments (eg ICS and omalizumab), appears higher in TH2-high phenotypes, but no specific treatments are available that work equally well in both TH2-high and TH2-low phenotypes. We explored whether TH2 biomarker status influenced responses to tiotropium in patients with moderate symptomatic asthma.


In two replicate Phase III, randomized, double-blind, placebo-controlled, parallel-group trials (NCT01172808/NCT01172821), patients with moderate symptomatic asthma, using medium-dose ICS (400-800 µg budesonide equivalent), were administered once-daily tiotropium Respimat® 5 µg or 2.5 µg, placebo, or salmeterol (active comparator without inferential analysis). Co-primary endpoints included peak and trough FEV1 response (difference from baseline) at 24 weeks. Pre-planned analyses (pooled population) were performed in TH2-high and TH2-low subgroups defined at baseline as total serum IgE ≤ or >430 µg/L) or blood eosinophils ≤ or >0.6×109/L.


Of 1545 patients in the full analysis set who received tiotropium or placebo, 915/1455 were reported with IgE >430 µg/L and 300/1461 with an eosinophil count of >0.6×109/L. Peak FEV1 improved with tiotropium versus placebo, independent of IgE (p<0.0001 both doses) and eosinophil count (p<0.0001 both doses). Trough FEV1 also improved with tiotropium versus placebo, irrespective of IgE (p<0.0001 both doses) and eosinophil count (p<0.005 both doses).


Once-daily tiotropium Respimat® as add-on to ICS reduces airflow obstruction in patients with moderate symptomatic asthma, independent of TH2 phenotype, and thus may potentially provide an important therapeutic option.

Funding source

Study supported by Boehringer Ingelheim. Previously presented at AAAAI 2014 in San Diego, CA, USA.



We thank Dr W.H. Yang for presenting this study on behalf of the authors.

Authors’ Affiliations

Allergy & Asthma Research Centre, Ottawa, Canada, K1Y 4G2
Division of Allergy and Immunology, Creighton University, Omaha, NE, USA
Department of Medicine, University of Cape Town, Cape Town, South Africa
Aarhus University Hospital, Aarhus, Denmark
NUPAIVA (Asthma Research Centre), Universidade Federal de Santa Catarina, Florianópolis, Brazil
Clinical Research of the Ozarks, Columbia, MO, USA
Department of Pulmonology, Intensive Care Medicine, Zentrum für Innere Medizin, Klinik I, University Clinic Rostock, Rostock, Germany
TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany
Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany
Department of Pulmonary Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands


© Yang et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.